Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus ULTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus ULTRACEF.
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER vs ULTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Cefadroxil, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis. It is bactericidal against susceptible organisms.
1-2 g IV every 6-8 hours; maximum 12 g/day.
250 mg orally every 6 hours or 500 mg orally every 12 hours for uncomplicated urinary tract infections; 1 g orally every 12 hours for complicated urinary tract infections.
None Documented
None Documented
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
0.5–1.2 hours in normal renal function; prolonged to 2–4 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Approximately 90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; less than 1% is excreted in feces via biliary elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic